Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CXR-H5222 | Human | Human CXADR / CAR Protein, His Tag |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Upacicalcet | SK-1403; AJT-240 | Approved | Ajinomoto Co Inc | ウパシタ, Upasita | Japan | Hyperparathyroidism, Secondary | Sanwa Kagaku Kenkyusho Co Ltd | 2021-06-23 | Hyperparathyroidism, Secondary | Details |
| Parathyroid hormone (Shire) | NPSP-795; rhPTH (1-84); rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558; SHP-635; SHP-634; ALX-111; 423562; EBP-05; EB-612 | Approved | Shire | Natpara, Preotact, Natpar | United States | Hypoparathyroidism | Nps Pharmaceuticals, Inc | 2006-04-24 | Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Psoriasis; Hypoparathyroidism; Hyperparathyroidism | Details |
| Cinacalcet Hydrochloride | AMG-073.HCl; NPS-1493; AMG-073; KRN-1493 | Approved | Amgen Inc | Parareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/Mimpara | United States | Hypercalcemia; Hyperparathyroidism, Secondary | Amgen Inc | 2004-03-08 | Hyperparathyroidism, Secondary; Rejection of renal transplantation; Hypophosphatemia; Edema, Cardiac; Parathyroid Neoplasms; Nephrosis; Kidney Diseases; Hypercalcemia; Hyperparathyroidism, Primary; Prostatic Neoplasms; Osteomalacia; Renal Insufficiency, Chronic; Hyperparathyroidism; Kidney Failure, Chronic; Chronic Kidney Disease-Mineral and Bone Disorder | Details |
| Etelcalcetide Hydrochloride | ONO-5163; KAI-4169; AMG-416; KAI-4169-HCl | Approved | Amgen Inc | Parsabiv | EU | Hyperparathyroidism, Secondary | Amgen Europe Bv | 2016-11-11 | Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic; Kidney Failure, Chronic | Details |
| Strontium Ranelate | S-12911; S-12911-2; FK-481 | Approved | Laboratoires Servier | Osseor, Protos, Protelos, 欧思美 | Mainland China | Osteoporosis, Postmenopausal | Les Laboratoires Servier | 2004-09-20 | Osteoporosis, Postmenopausal | Details |
| Evocalcet | KHK-7580; MT-4580 | Approved | Mitsubishi Tanabe Pharma Corp | Orkedia | Japan | Hyperparathyroidism, Secondary | Kyowa Hakko Kirin Co Ltd | 2018-03-23 | Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism | Details |
| Upacicalcet | SK-1403; AJT-240 | Approved | Ajinomoto Co Inc | ウパシタ, Upasita | Japan | Hyperparathyroidism, Secondary | Sanwa Kagaku Kenkyusho Co Ltd | 2021-06-23 | Hyperparathyroidism, Secondary | Details |
| Parathyroid hormone (Shire) | NPSP-795; rhPTH (1-84); rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558; SHP-635; SHP-634; ALX-111; 423562; EBP-05; EB-612 | Approved | Shire | Natpara, Preotact, Natpar | United States | Hypoparathyroidism | Nps Pharmaceuticals, Inc | 2006-04-24 | Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Psoriasis; Hypoparathyroidism; Hyperparathyroidism | Details |
| Cinacalcet Hydrochloride | AMG-073.HCl; NPS-1493; AMG-073; KRN-1493 | Approved | Amgen Inc | Parareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/Mimpara | United States | Hypercalcemia; Hyperparathyroidism, Secondary | Amgen Inc | 2004-03-08 | Hyperparathyroidism, Secondary; Rejection of renal transplantation; Hypophosphatemia; Edema, Cardiac; Parathyroid Neoplasms; Nephrosis; Kidney Diseases; Hypercalcemia; Hyperparathyroidism, Primary; Prostatic Neoplasms; Osteomalacia; Renal Insufficiency, Chronic; Hyperparathyroidism; Kidney Failure, Chronic; Chronic Kidney Disease-Mineral and Bone Disorder | Details |
| Etelcalcetide Hydrochloride | ONO-5163; KAI-4169; AMG-416; KAI-4169-HCl | Approved | Amgen Inc | Parsabiv | EU | Hyperparathyroidism, Secondary | Amgen Europe Bv | 2016-11-11 | Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic; Kidney Failure, Chronic | Details |
| Strontium Ranelate | S-12911; S-12911-2; FK-481 | Approved | Laboratoires Servier | Osseor, Protos, Protelos, 欧思美 | Mainland China | Osteoporosis, Postmenopausal | Les Laboratoires Servier | 2004-09-20 | Osteoporosis, Postmenopausal | Details |
| Evocalcet | KHK-7580; MT-4580 | Approved | Mitsubishi Tanabe Pharma Corp | Orkedia | Japan | Hyperparathyroidism, Secondary | Kyowa Hakko Kirin Co Ltd | 2018-03-23 | Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Encaleret sulfate | MK-5442; JTT-305; CLTX-305 | Phase 3 Clinical | Japan Tobacco (Hong Kong) Ltd | Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal; Hypoparathyroidism | Details |
| LNP-1892 | LNP-1892 | Phase 2 Clinical | Lupin Ltd | Hyperparathyroidism | Details |
| DS-9194b | DS-9194b | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Osteoporosis | Details |
| OSM-0205 | OSM-0205 | Phase 1 Clinical | Yale University, Osmol Therapeutics Inc | Peripheral Nervous System Diseases; Peripheral Nerve Injuries | Details |
| RT-102(Rani) | RT-102 | Phase 1 Clinical | Rani Therapeutics Holdings Inc | Osteoporosis | Details |
| Encaleret sulfate | MK-5442; JTT-305; CLTX-305 | Phase 3 Clinical | Japan Tobacco (Hong Kong) Ltd | Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal; Hypoparathyroidism | Details |
| LNP-1892 | LNP-1892 | Phase 2 Clinical | Lupin Ltd | Hyperparathyroidism | Details |
| DS-9194b | DS-9194b | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Osteoporosis | Details |
| OSM-0205 | OSM-0205 | Phase 1 Clinical | Yale University, Osmol Therapeutics Inc | Peripheral Nervous System Diseases; Peripheral Nerve Injuries | Details |
| RT-102(Rani) | RT-102 | Phase 1 Clinical | Rani Therapeutics Holdings Inc | Osteoporosis | Details |
This web search service is supported by Google Inc.
A-Z
